BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10418922)

  • 1. Vaccination with Rev and Tat against AIDS.
    Osterhaus AD; van Baalen CA; Gruters RA; Schutten M; Siebelink CH; Hulskotte EG; Tijhaar EJ; Randall RE; van Amerongen G; Fleuchaus A; Erfle V; Sutter G
    Vaccine; 1999 Jun; 17(20-21):2713-4. PubMed ID: 10418922
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
    Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
    Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
    Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
    DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.
    van Baalen CA; Pontesilli O; Huisman RC; Geretti AM; Klein MR; de Wolf F; Miedema F; Gruters RA; Osterhaus AD
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1913-8. PubMed ID: 9266987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.
    Addo MM; Altfeld M; Rosenberg ES; Eldridge RL; Philips MN; Habeeb K; Khatri A; Brander C; Robbins GK; Mazzara GP; Goulder PJ; Walker BD;
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1781-6. PubMed ID: 11172028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.
    Gruters RA; van Baalen CA; Osterhaus AD
    Vaccine; 2002 May; 20(15):2011-5. PubMed ID: 11983265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, Tat and Rev.
    Chenciner N; Randrianarison-Jewtoukoff V; Delpeyroux F; Hanania N; Pedroza Martins L; Stratford Perricaudet L; Perricaudet M; Wain-Hobson S
    AIDS Res Hum Retroviruses; 1997 Jun; 13(9):801-6. PubMed ID: 9171225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV regulatory and accessory proteins: new targets for vaccine development.
    Robert-Guroff M
    DNA Cell Biol; 2002 Sep; 21(9):597-8. PubMed ID: 12396601
    [No Abstract]   [Full Text] [Related]  

  • 10. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates.
    Wang B; Boyer J; Srikantan V; Coney L; Carrano R; Phan C; Merva M; Dang K; Agadjanan M; Gilbert L
    DNA Cell Biol; 1993 Nov; 12(9):799-805. PubMed ID: 8216851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).
    Cafaro A; Titti F; Fracasso C; Maggiorella MT; Baroncelli S; Caputo A; Goletti D; Borsetti A; Pace M; Fanales-Belasio E; Ridolfi B; Negri DR; Sernicola L; Belli R; Corrias F; Macchia I; Leone P; Michelini Z; ten Haaft P; Buttò S; Verani P; Ensoli B
    Vaccine; 2001 Apr; 19(20-22):2862-77. PubMed ID: 11282197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
    Ensoli B; Cafaro A
    J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames.
    Klase Z; Donio MJ; Blauvelt A; Marx PA; Jeang KT; Smith SM
    Retrovirology; 2006 Jan; 3():1. PubMed ID: 16398928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.
    Stittelaar KJ; Gruters RA; Schutten M; van Baalen CA; van Amerongen G; Cranage M; Liljeström P; Sutter G; Osterhaus AD
    Vaccine; 2002 Jul; 20(23-24):2921-7. PubMed ID: 12126903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDS. Escape from the immune system.
    Walker BD; Goulder PJ
    Nature; 2000 Sep; 407(6802):313-4. PubMed ID: 11014174
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection.
    Guillon C; Stankovic K; Ataman-Onal Y; Biron F; Verrier B
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1283-92. PubMed ID: 17209772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTL responses to regulatory proteins Tat and Rev in HIV-1 B'/C virus-infected individuals.
    Jia MM; Hong KX; Chen JP; Liu HW; Liu S; Zhang XQ; Zhao HJ; Shao YM
    Biomed Environ Sci; 2008 Aug; 21(4):314-8. PubMed ID: 18837295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
    Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
    Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
    Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.